| Code | CSB-RA006254MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ulocuplumab, targeting the C-X-C chemokine receptor type 4 (CXCR4). CXCR4 is a G protein-coupled receptor that binds to its natural ligand CXCL12 (SDF-1), playing critical roles in hematopoietic stem cell homing, lymphocyte trafficking, and embryonic development. The CXCR4/CXCL12 signaling axis is implicated in numerous pathological conditions, including cancer metastasis, tumor progression, HIV-1 infection, and hematological malignancies. Aberrant CXCR4 expression has been documented in over 23 different cancer types, where it promotes cell survival, angiogenesis, and metastatic spread to distant organs.
Ulocuplumab is a fully humanized IgG4 monoclonal antibody that specifically binds to CXCR4, blocking its interaction with CXCL12 and inhibiting downstream signaling pathways. This biosimilar provides researchers with a valuable tool for investigating CXCR4-mediated mechanisms in oncology, immunology, and stem cell biology. It is particularly useful for studies examining cancer cell migration, tumor microenvironment interactions, and therapeutic intervention strategies targeting the CXCR4 pathway.
There are currently no reviews for this product.